TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01298271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
Study: NCT03296527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin delta
Description: REKOVELLE (FE 999049) was fixed throughout the stimulation period.
Study: NCT02732873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FibroFix Meniscal Scaffold
Description: FibroFix™ Meniscus scaffold is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
Study: NCT01268111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: ERgocaclciferol 50,000 units weekly for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT01555216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single injection posterior tibial nerve block
Description: 5 ml of 0.5% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posterior tibial nerve catheter
Description: 5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
Study: NCT01049321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DASH diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: a usual diabetic diet
Study: NCT02134652

Intervention type: OTHER
Intervention: diagnostic bedside ultrasound
Description: Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~* FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~* Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.
Study: NCT02996864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Detours App
Description: The app features:~* Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.~* User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.~* Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fat Secret App
Description: Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
Study: NCT00589953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour.
Study: NCT03637010

Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast in the Classroom
Description: For all breakfasts, the students will use the 'grab and go' approach from hallway kiosks. The students will take the breakfasts back to their respective classroom and consume them there.
Study: NCT00589953

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
Study: NCT02164227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory pattern
Study: NCT02117375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord MRI follow-up
Description: Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord MRI follow-up
Description: Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical follow-up
Description: Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brain MRI follow-up
Study: NCT01074164

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-care treatment for AD
Description: Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-patch pellet
Description: The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
Study: NCT05404061

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gut hormones
Description: Their first visit will act as an acclimatisation visit and participants will be infused subcutaneously with a triple gut hormone infusion (GLP-1, PYY and OXM). This will not only allow us to acclimatise the study volunteer to the study visits, but also allow us to test for subject tolerability of the gut hormones.~For the next two visits participants will be randomised in a single-blinded fashion to a subcutaneous infusion of either:~1. 0.9% saline,~2. GLP-1
Study: NCT02993003

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasopharyngeal probe
Description: nasopharyngeal probe insertion

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasopharyngeal probe
Description: nasopharyngeal probe insertion

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasopharyngeal probe
Description: nasopharyngeal probe insertion
Study: NCT00615277

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 600 mg EPA 120mg DHA daily, 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 600 mg EPA 120mg DHA daily, 16 weeks
Study: NCT03547713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social feedback
Description: Social feedback regarding performance of a public speech is delivered to participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-referential paradigm
Description: Exposure to traits varying in valence (positive vs. negative) and social domain (power vs. affiliation)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reward vs. punishment task
Description: Reception of monetary gains vs. losses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional reactivity task
Description: Exposure to emotional faces vs. shapes
Study: NCT04019743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 1 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 1 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 1 Tab. 1T
Description: single oral administration under fasting condition
Study: NCT01982955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Tepotinib was administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment. RP2D was determined as per safety monitoring committee (SMC) discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib was administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment.
Study: NCT04019743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 1 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 1 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 1 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 2 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 2 Tab. 1T
Description: single oral administration under fasting condition
Study: NCT03071172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Choriogonadotropin alfa Solution for Injection
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Soft Capsules
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Study: NCT04019743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 2 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 2 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 2 Tab. 1T
Description: single oral administration under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 16/10/40mg formulation 2 Tab. 1T
Description: single oral administration under fasting condition
Study: NCT02477995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP Vaccine A
Description: Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP Vaccine B
Description: Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
Study: NCT03656419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: aPDT with methylene blue and red led irradiation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: aPDT with methylene blue and red led irradiation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tongue scraper
Description: Tongue scraper 10 times from de back to the top.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tongue scraper
Description: Tongue scraper 10 times from de back to the top.
Study: NCT03257631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: : Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.
Study: NCT04172441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: Glucagon analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasiglucagon
Description: Glucagon analogue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for dasiglucagon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for dasiglucagon
Study: NCT00741481

Intervention type: PROCEDURE
Intervention: FDG-PET imaging
Description: FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
Study: NCT03232385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-US Fusion Arm
Description: Use of Clear Guide SCENERGY for MR-US fusion guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal Biopsy or Ablation
Description: Standard of Care
Study: NCT02088983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CDP-Choline
Description: Capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Capsule
Study: NCT01340157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
Study: NCT03468907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine 600mg
Description: Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine 600mg
Description: Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300mg
Description: Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.
Study: NCT01810666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
Study: NCT04398758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SanaCutan Basiscreme
Description: In this study, the SanaCutan Basiscreme will be used as a cream for twice daily application on the whole body (eyes and mucous membranes have to be omitted) for a duration of 6 months (main phase) or 12 months (main + follow-up phase) or less (if the child develops atopic dermatitis).
Study: NCT00394212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transoral Suturing
Description: suturing of anastomosis

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Endoscopy
Description: suturing not performed
Study: NCT00978328

Intervention type: DRUG
Intervention: oxycodone immediate release (OXYRX)
Description: Characteristics of pts. receiving prescription medications containing OXYRX
Study: NCT01267396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline Hydrochloride Tablets 100 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline Hydrochloride Tablets 100 mg
Study: NCT03606681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Trioxide Aggregate
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TheraCal LC
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraCal LC
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraCal LC
Description: After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.